Genmab A/S (GMAB) |
|
25.01 0.75 (3.09%)
|
02-20 16:00 |
|
Open: |
24.7 |
Pre. Close: |
24.26 |
|
High:
|
25.1389 |
Low:
|
24.33 |
|
Volume:
|
980,005 |
Market Cap:
|
15801M |
|
|
|
|
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the trea |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
25.155 - 25.229 |
25.229 - 25.313 |
|
Low:
|
24.105 - 24.196 |
24.196 - 24.297 |
|
Close:
|
24.848 - 24.987 |
24.987 - 25.142 |
|
Technical analysis |
as of: 2020-02-20 4:40:21 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 29.36 One year: 34.30 |
| Support: |
Support1: 23.34 Support2: 22.23 |
| Resistance: |
Resistance1: 25.14 Resistance2: 29.36 |
| Pivot: |
23.96 |
| Moving Average: |
MA(5): 24.22 MA(20): 23.64
MA(100): 22.23 MA(250): 19.85 |
| MACD: |
MACD(12,26): 0.46 Signal(9): 0.40 |
| Stochastic oscillator: |
%K(14,3): 84.71 %D(3): 79.89 |
| RSI: |
RSI(14): 71.48 |
| 52-week: |
High: 25.14 Low: 16.33 Change(%): 52.9 |
| Average Vol(K): |
3-Month: 31557 10-Days: 47481 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.GMAB has closed above the upper band by 7.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 12.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
2020-01-22
Genmab earns $150M Darzalex milestone from J&J
Triggered by the achievement of $3B in global Darzalex (daratumumab) sales in 2019, Genmab A/S (NASDAQ:GMAB) earns a $150M milestone payment from Johnson &
2020-01-22
Genmab Announces 2019 Net Sales Figures for DARZALEX® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen
Company Announcement Net trade sales of DARZALEX in 2019 totaled USD 2,998 millionGenmab to receive milestone payment of USD 150 million in DARZALEX…
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NasdaqGS |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
649.11 |
| Shares Float (M) |
642.32 |
|
% Held by Insiders
|
|
|
% Held by Institutions
|
3.67 |
|
Shares Short (K)
|
669 |
|
Shares Short P. Month (K)
|
|
Stock Financials |
|
EPS
|
|
|
Book Value (p.s.)
|
|
|
PEG Ratio
|
|
|
Profit Margin
|
41.97 |
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
7.1 |
|
Return on Equity (ttm)
|
15.6 |
|
Qtrly Rev. Growth
|
73.7 |
|
Gross Profit (p.s.)
|
4.668 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
199.70 |
|
Operating Cash Flow (M)
|
|
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
P/E
|
|
|
P/E Growth Ratio
|
|
|
P/BV
|
|
|
P/S
|
|
|
P/CF
|
|
Dividends & Splits |
|
Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Forward Dividend
|
|
|
Last Split Date
|
2018-04-30 |
|
Last Split Ratio
|
5 |
|
7 Binary Options
|
|
Your Ad Here
|
|
